Dermata Therapeutics, Inc. has achieved a significant milestone by receiving effectiveness for its S-3 registration statement. This allows the company to proceed with its plans for capital raising, which is crucial for its ongoing development and operations.

Background

Dermata Therapeutics, Inc. is classified under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker DRMA. As an emerging growth company, Dermata focuses on developing innovative therapies to address unmet medical needs.

What the Filing Says

The recent filing, dated October 20, 2026, confirms that the S-3 registration statement has been deemed effective. This filing is a critical step for Dermata as it seeks to enhance its financial resources.

Impact

This development may impact various stakeholders, including investors and competitors within the pharmaceutical preparations industry. With enhanced capabilities to raise capital, Dermata may accelerate its research and development efforts, potentially influencing market dynamics.

What's Next

The filing does not say what happens next.

Company Details

Dermata Therapeutics, Inc. is incorporated in Delaware and operates under the fiscal year ending on December 31. The company is part of the 03 Life Sciences organization, which reflects its focus on innovative medical solutions.

Filing Specifics

The filing was submitted under the SEC Act of 1933, with the SEC file number 333-299391. It was officially accepted on October 20, 2026, at 17:00:00, marking a pivotal moment in the company’s journey toward enhanced capital accessibility.

Contact Information

Dermata Therapeutics can be reached at their business address located at 3525 Del Mar Heights Rd., #322, San Diego, CA 92130. For inquiries, they can be contacted via phone at (858)-223-0882.

What the Filing Does Not Include

The filing does not provide specific details regarding the intended use of the capital to be raised or any timelines for upcoming projects or initiatives following the effectiveness of the S-3 registration statement.